The University of Texas MD Anderson Cancer Center reported promising early outcomes from trials of VT3989, a first‑in‑class YAP‑TEAD inhibitor, in refractory mesothelioma and other solid tumors. Investigators observed disease control in heavily pretreated patients and described on‑target pharmacology consistent with Hippo pathway inhibition. VT3989 targets the YAP‑TEAD transcriptional complex, a downstream effector of the Hippo pathway implicated in tumor growth and therapy resistance. The sponsor highlighted the agent’s potential for tumors driven by YAP/TEAD signaling and signaled plans for expanded cohorts and combination studies. Researchers noted the need for further dose‑finding and biomarker development to identify patients most likely to benefit.